|
| related topics |
| {product, candidate, development} |
| {acquisition, growth, future} |
| {cost, operation, labor} |
| {product, market, service} |
| {personnel, key, retain} |
| {property, intellectual, protect} |
| {control, financial, internal} |
| {customer, product, revenue} |
| {operation, international, foreign} |
|
|
We expect intense competition in our target markets, which could render our products obsolete, result in significant price reductions or substantially limit the volume of products that we sell. This would limit our ability to compete and achieve profitability. If we cannot continuously develop and commercialize new products, our revenue may not grow as intended.
We may encounter difficulties in integrating recently completed or future acquisitions that could adversely affect our business.
We have only recently achieved profitability and may not be able to remain profitable.
The growth and profitability of our oligo business depends on a third party.
We have a limited history of commercial sales of systems and consumable products, and our success depends on our ability to develop commercially successful products and on market acceptance of our new and relatively unproven technologies.
Any inability to adequately protect our proprietary technologies could harm our competitive position.
Our manufacturing capacity may limit our ability to sell our products.
Our sales, marketing and technical support organization may limit our ability to sell our products.
If we are unable to develop and maintain operation of our manufacturing capability, we may not be able to launch or support our products in a timely manner, or at all.
If we are unable to find third-party manufacturers to manufacture components of our products, we may not be able to launch or support our products in a timely manner, or at all.
We may encounter difficulties in managing our growth. These difficulties could increase our losses.
We may need additional capital in the future. If additional capital is not available on acceptable terms, we may have to curtail or cease operations.
If we lose our key personnel or are unable to attract and retain additional personnel, we may be unable to achieve our goals.
A significant portion of our sales are to international customers.
Full 10-K form ▸
|
|
| related documents |
| 1013238--3/31/2006--ARADIGM_CORP |
| 1020214--2/27/2006--CERUS_CORP |
| 1001233--3/16/2006--SANGAMO_BIOSCIENCES_INC |
| 1333248--3/16/2009--CADENCE_PHARMACEUTICALS_INC |
| 908259--3/14/2007--OXIGENE_INC |
| 897075--3/14/2007--REPROS_THERAPEUTICS_INC. |
| 1063665--9/23/2010--CORGENIX_MEDICAL_CORP/CO |
| 908259--3/14/2008--OXIGENE_INC |
| 908259--3/14/2006--OXIGENE_INC |
| 874443--3/31/2006--GENELABS_TECHNOLOGIES_INC_/CA |
| 1001233--3/1/2007--SANGAMO_BIOSCIENCES_INC |
| 908259--3/16/2010--OXIGENE_INC |
| 805326--3/17/2008--EMISPHERE_TECHNOLOGIES_INC |
| 907562--3/3/2006--DYAX_CORP |
| 907562--3/13/2007--DYAX_CORP |
| 1010086--3/13/2008--SIGA_TECHNOLOGIES_INC |
| 1028358--3/31/2008--GENITOPE_CORP |
| 873303--3/16/2007--AVI_BIOPHARMA_INC |
| 873303--3/16/2006--AVI_BIOPHARMA_INC |
| 817785--4/4/2007--IMMUNE_RESPONSE_CORP |
| 1038133--3/31/2006--HESKA_CORP |
| 1038133--3/30/2007--HESKA_CORP |
| 886163--3/31/2006--LIGAND_PHARMACEUTICALS_INC |
| 1017491--3/12/2008--NEXMED_INC |
| 1120438--3/15/2006--THIRD_WAVE_TECHNOLOGIES_INC_/WI |
| 708717--10/15/2007--ALFACELL_CORP |
| 1038133--3/16/2009--HESKA_CORP |
| 1038133--3/3/2008--HESKA_CORP |
| 1038133--2/22/2010--HESKA_CORP |
| 1120438--3/16/2007--THIRD_WAVE_TECHNOLOGIES_INC_/WI |
|